Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Common Stock (NQ:TVGN)

0.3377 +0.0177 (+5.53%)
Streaming Delayed Price Updated: 11:45 AM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tevogen Bio Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Donates Personal Shares to Support Local Fire Department
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
From Tevogen Bio Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.